Regulatory framework holding back biotech growth: Biocon chief

Regulatory framework holding back biotech growth: Biocon chief

Bangalore: Biocon Ltd chairman and managing director Kiran Mazumdar-Shaw said India’s regulatory environment was the only factor holding back the country’s progress in biotechnology as the company opened a consolidated basic research centre in life sciences in Bangalore on Thursday.

As for advancing research, she said that given the interdisciplinary nature of science, it was not possible to “pick and choose where you want to be".

“Science is all-pervading. There is nanotechnology, biotechnology, stem cells and so on. You cannot say this is permissible and that is not. It is all integrated. There has to be a cohesive, well-aligned ecosystem," she said.

Watch Video

Kiran Mazumdar Shaw talks about the areas Biocon’s research and development will focus on.

Loading video

The new research facility was set up at a cost of 100 crore and, given the investments in equipment and allied facilities over several years, the total cost is estimated to be around 250 crore, she said. It brings together 300 of Biocon’s existing scientists under one roof in an advanced facility.

“Biocon’s research so far has been done in fragmented labs, which are working in silos. This is about an integrated centre enabling a multidisciplinary approach to research and development (R&D). R&D is very iterative, and to do that faster you need groups to talk to each other," said Mazumdar-Shaw, who has built Biocon into India’s largest biotech firm since founding it in 1978 with an investment of 10,000.

Watch Video

Kurt Wüthrich says India needs to focus on creating strong educational institutions if it wants to produce innovative drug researchers.

Loading Video...

The facility’s mandate is to be “a centre of excellence of proprietary skills, IP (intellectual property) creation, about taking risks and betting on important new technologies and therapeutics," she said. “We don’t want incremental innovation, but breakthroughs."

Biocon’s research is focused on diabetes, cancer and auto-immune diseases.

The centre was inaugurated by the 2002 Nobel Prize winner for chemistry, Kurt Wüthrich, who said in an interview that the centre’s mandate in drug discovery is an important one, given the constraints that the pharmaceutical industry faces worldwide.

“Big pharma companies are today run by lawyers who are scared about introducing a new drug," the Swiss chemist said. “We have examples of drugs, which have helped millions of people over many years, being taken off the market because of a few severe side effects. There is really a need for innovative research."

sridhar.c@livemint.com

Close